Macitentan is a Small Molecule owned by Johnson & Johnson, and is involved in 46 clinical trials, of which 33 were completed, 12 are ongoing, and 1 is planned.

Macitentan (ACT-064992, Opsumit) is a dual endothelin receptor (ET) antagonist. Endothelin receptors are over expressed in many tumor cell types. The drug candidate blocks the binding of endothelin isoform 1 (ET-1) to type-A and type-B receptors on both the tumor cells and the endothelial cells in the tumor vasculature. The inhibition of ET-1 mediated signal transduction decreases tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1 is also linked to the dysfunction of the L-arginine-nitric oxide pathway. ET-1 play important role in recruiting fibroblasts and formation of fibrotic tissue and lesion.

The revenue for Macitentan is expected to reach a total of $8.7bn through 2030. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Macitentan NPV Report.

Macitentan was originated by Actelion Pharmaceuticals and is currently owned by Johnson & Johnson.

Macitentan Overview

Macitentan (ACT-064992, Opsumit, Zependo) is a novel dual endothelin receptor antagonist (ERA). It is formulated as film coated tablets for the oral route of administration. Macitentan s indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for pulmonary arterial hypertension.

Macitentan (ACT-064992) is under development for the treatment of congenital heart disease with fontan-palliated, chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension (PAH) in pediatric patients, combined pre- and post-capillary pulmonary hypertension (CpcPH) and heart failure with preserved ejection fraction (diastolic heart failure), pulmonary vascular disease. It was also under development for the treatment of idiopathic pulmonary fibrosis, glioblastoma and digital ulcers associated with systemic sclerosis, chronic thromboembolic pulmonary hypertension (CTEPH) and Eisenmenger syndrome.

Johnson & Johnson Overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.

Quick View – Macitentan

Report Segments
  • Innovator (NME)
Drug Name
  • Macitentan
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Oncology
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.